SCG Cell Therapy has announced late-breaking data from its Phase I trial of SCG101, a first-in-class autologous hepatitis B virus (HBV)-specific T-cell receptor-engineered T cell (TCR-T) therapy targeting hepatitis B surface antigen (HBsAg).  

The data was presented at the 2024 AASLD Liver Meeting in San Diego, United States.  

In the Phase I clinical trial, SCG101 exhibited promising antiviral activity in patients with advanced HBV-related hepatocellular carcinoma (HBV-HCC). 

Among the 12 patients treated with a single intravenous dose of SCG101 at 5.0×107 ~ 1.0×108 TCR+ T cells/kg, all patients demonstrated a significant reduction in serum HBsAg levels, with 11 out of 12 (92%) patients achieving a reduction of 1.0 to 4.6 log10, and the levels remaining below 100 IU/mL throughout the follow-up period of up to one year.  

Notably, four patients (33%) experienced HBsAg loss within 21 days following a single infusion of SCG101 and which persisted throughout the follow-up. 

HBV is a leading cause of liver cancer, responsible for 50-80% of hepatocellular carcinoma cases globally. 

SCG101 is designed to target a specific HBV peptide presented on infected cells, as well as hepatocytes with HBV DNA integration. By triggering both cytolytic and non-cytolytic mechanisms, SCG101 can eliminate HBV-infected hepatocytes as well as premalignant and HBV-HCC cells with HBV-DNA integration.   

“The positive data from our Phase I trial marks a significant milestone in the development of SCG101, our first-in-class HBV-specific TCR-T therapy. These results not only demonstrate the potential of SCG101 to achieve meaningful and durable antiviral responses in patients, but also underscore the unique approach we are taking in HBV-specific TCR T cell therapy”, said Christy Ma, Chief Executive Officer of SCG Cell Therapy.

Diana Spencer, Senior Digital Content Editor, DDW